Stay Up to Date
with SHINE

Our team joined hundreds of community members at the Town Square Pavilion for the 31st annual walk. This year, thanks to the incredible generosity of our employees and vendors, we raised over $8,600 for the American Heart Association

Transformational leaders join SHINE to guide the company through next stages of growth and profitability

TOFE 2024 spotlights fusion's future: collaboration is key, near-term value creation crucial. Industry leaders, including SHINE, discuss workforce challenges and simplifying fusion tech. Dive into insights shaping our industry's path forward.

AuntMinnie- The European Commission has approved a $2.17 billion proposal by the Netherlands to fund construction of a new medical isotope production facility in Petten.

U.S.-based SHINE Technologies has been awarded $32M from the Department of Energy’s National Nuclear Security Administration (DOE/NNSA).

FLARE® enables faster, more comprehensive radiation effects testing to better protect national security, including mission critical components and infrastructure

SHINE Technologies is developing a medical isotope production facility in Janesville.

To fund its vision of generating power from fusion, SHINE Technologies aims first to revolutionize medical isotope production

The award will support progress on Chrysalis, SHINE’s large-scale medical isotope production facility in Janesville, Wisconsin

Greg Piefer, PhD, founder and CEO of SHINE Technologies, says the company is about two years away from launching a new facility called Chrysalis, which is poised to become the world’s largest producer of medical isotopes.

Cincinnati Children’s Hospital needed Lu-177 for scanner calibration, a crucial step in ensuring the safe and effective delivery of targeted radiotherapy to young patients. It was Sunday, and the dose was needed in-hand by Thursday to keep a patient’s treatment schedule on course

SHINE Technologies is partnering with Zeno Power, a developer of commercial radioisotope power systems.

SHINE and Zeno enter an MOU to develop radioisotope supply chain for power systems that enable persistent operations from the seabed to the lunar surface

Radioisotope producer SHINE Technologies announced a partnership with radiopharmaceutical developer Blue Earth Therapeutics to use SHINE’s first supply of non-carrier-added lutetium-177 chloride, normally in short supply, for a prostate cancer trial.

Blue Earth Therapeutics will leverage SHINE’s non-carrier added lutetium-177 chloride, Ilumira, in a new treatment for prostate cancer undergoing clinical trials